These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

8407 related items for PubMed ID: 1901514

  • 1. Formation of neutralizing antibodies against natural interferon-beta, but not against recombinant interferon-gamma during adjuvant therapy for high-risk malignant melanoma patients.
    Dummer R, Müller W, Nestle F, Wiede J, Dues J, Lechner W, Haubitz I, Wolf W, Bill E, Burg G.
    Cancer; 1991 May 01; 67(9):2300-4. PubMed ID: 1901514
    [Abstract] [Full Text] [Related]

  • 2. Phase II trial of a combination of interferon-beta ser and interferon-gamma in patients with advanced malignant melanoma.
    Schiller JH, Storer B, Bittner G, Willson JK, Borden EC.
    J Interferon Res; 1988 Oct 01; 8(5):581-9. PubMed ID: 3148669
    [Abstract] [Full Text] [Related]

  • 3. Adjuvant immunotherapy in malignant melanoma: impact of antibody formation against interferon-alpha on immunoparameters in vivo.
    Davis-Daneshfar A, Böni R, von Wussow P, Joller H, Burg G, Dummer R.
    J Immunother; 1997 May 01; 20(3):208-13. PubMed ID: 9181459
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta ser.
    Larocca AP, Leung SC, Marcus SG, Colby CB, Borden EC.
    J Interferon Res; 1989 Sep 01; 9 Suppl 1():S51-60. PubMed ID: 2809278
    [Abstract] [Full Text] [Related]

  • 5. Low frequency of neutralizing antibodies against natural interferon-beta during adjuvant therapy for Japanese patients with melanoma.
    Kageshita T, Yamamoto A, Yamazaki N, Ishihara K, Ono T.
    J Dermatol Sci; 1999 Apr 01; 19(3):208-12. PubMed ID: 10215194
    [Abstract] [Full Text] [Related]

  • 6. Neutralizing interferon beta antibodies in melanoma patients treated with recombinant and natural interferon beta.
    Fierlbeck G, Schreiner T, Schaber B, Walser A, Rassner G.
    Cancer Immunol Immunother; 1994 Oct 01; 39(4):263-8. PubMed ID: 7954528
    [Abstract] [Full Text] [Related]

  • 7. Induction of the interleukin-2 receptor (p55) by interferons.
    Onji M, Yamaguchi S, Masumoto T, Akbar SM, Kajino K, Ohta Y.
    J Interferon Res; 1991 Aug 01; 11(4):237-41. PubMed ID: 1680935
    [Abstract] [Full Text] [Related]

  • 8. Loss of interferon antibodies during prolonged continuous interferon-alpha 2a therapy in hairy cell leukemia.
    Steis RG, Smith JW, Urba WJ, Venzon DJ, Longo DL, Barney R, Evans LM, Itri LM, Ewel CH.
    Blood; 1991 Feb 15; 77(4):792-8. PubMed ID: 1704264
    [Abstract] [Full Text] [Related]

  • 9. Assessment of the antigenic response in humans to a recombinant mutant interferon beta.
    Konrad MW, Childs AL, Merigan TC, Borden EC.
    J Clin Immunol; 1987 Sep 15; 7(5):365-75. PubMed ID: 3308943
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the effects of three different treatment regimens of recombinant interferons (r-IFN alpha, r-IFN gamma, and r-IFN alpha + cimetidine) in disseminated malignant melanoma.
    Steiner A, Wolf C, Pehamberger H.
    J Cancer Res Clin Oncol; 1987 Sep 15; 113(5):459-65. PubMed ID: 3114265
    [Abstract] [Full Text] [Related]

  • 11. Phase-II study of recombinant alpha 2-interferon in advanced malignant melanoma.
    Coates A, Rallings M, Hersey P, Swanson C.
    J Interferon Res; 1986 Feb 15; 6(1):1-4. PubMed ID: 2871116
    [Abstract] [Full Text] [Related]

  • 12. Anti-interferon antibodies to interferon-alpha 2b: results of comparative assays and clinical perspective.
    Spiegel RJ, Jacobs SL, Treuhaft MW.
    J Interferon Res; 1989 Sep 15; 9 Suppl 1():S17-24. PubMed ID: 2553829
    [Abstract] [Full Text] [Related]

  • 13. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity.
    Oberg K, Alm G, Magnusson A, Lundqvist G, Theodorsson E, Wide L, Wilander E.
    J Natl Cancer Inst; 1989 Apr 05; 81(7):531-5. PubMed ID: 2466128
    [Abstract] [Full Text] [Related]

  • 14. Incidence of autoantibodies against type I and type II interferons in a cohort of systemic lupus erythematosus patients in Slovakia.
    Slavikova M, Schmeisser H, Kontsekova E, Mateicka F, Borecky L, Kontsek P.
    J Interferon Cytokine Res; 2003 Mar 05; 23(3):143-7. PubMed ID: 12716486
    [Abstract] [Full Text] [Related]

  • 15. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
    Schiller JH, Storer B, Witt PL, Nelson B, Brown RR, Horisberger M, Grossberg S, Borden EC.
    Cancer Res; 1990 Aug 01; 50(15):4588-94. PubMed ID: 2114942
    [Abstract] [Full Text] [Related]

  • 16. Antibodies to interferon-alpha 2 in patients treated with interferon-alpha 2 for hairy cell leukemia.
    Bekisz JB, zur Nedden DL, Enterline JC, Zoon KC.
    J Interferon Res; 1989 Sep 01; 9 Suppl 1():S1-7. PubMed ID: 2809275
    [Abstract] [Full Text] [Related]

  • 17. Systemic therapy of advanced metastatic malignant melanoma with a combination of fibroblast interferon-beta and recombinant interferon-gamma.
    Kowalzick L, Weyer U, Lange P, Breitbart EW.
    Dermatologica; 1990 Sep 01; 181(4):298-303. PubMed ID: 2127402
    [Abstract] [Full Text] [Related]

  • 18. A phase I study of recombinant interleukin 2 plus recombinant beta-interferon.
    Krigel RL, Padavic-Shaller KA, Rudolph AR, Litwin S, Konrad M, Bradley EC, Comis RL.
    Cancer Res; 1988 Jul 01; 48(13):3875-81. PubMed ID: 3132324
    [Abstract] [Full Text] [Related]

  • 19. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
    Alatrash G, Hutson TE, Molto L, Richmond A, Nemec C, Mekhail T, Elson P, Tannenbaum C, Olencki T, Finke J, Bukowski RM.
    J Clin Oncol; 2004 Jul 15; 22(14):2891-900. PubMed ID: 15254058
    [Abstract] [Full Text] [Related]

  • 20. Changes in lymphocyte subsets following multiple administration of recombinant interleukin-2 plus recombinant interferon-beta or -gamma in tumor-bearing mice.
    Iigo M, Nishikata K, Nakajima Y, Moriyama M.
    Jpn J Cancer Res; 1989 Jun 15; 80(6):554-61. PubMed ID: 2527216
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 421.